GLORIA

GEOMAR Library Ocean Research Information Access

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
Filter
  • MDPI AG  (2)
  • 2020-2024  (2)
Material
Publisher
  • MDPI AG  (2)
Language
Years
  • 2020-2024  (2)
Year
  • 1
    Online Resource
    Online Resource
    MDPI AG ; 2022
    In:  Journal of Clinical Medicine Vol. 11, No. 22 ( 2022-11-11), p. 6686-
    In: Journal of Clinical Medicine, MDPI AG, Vol. 11, No. 22 ( 2022-11-11), p. 6686-
    Abstract: Long-term systemic glucocorticoids and non-specific immunosuppressants remain the mainstay of treatment for refractory scleritis, and result in serious side-effects and repeated inflammation flares. To assess the efficacy and safety of additional adalimumab, patients diagnosed with refractory non-infectious scleritis were enrolled. They were assigned to the conventional-therapy (CT, using systemic glucocorticoids and other immunosuppressants) group or the adalimumab-plus-conventional-therapy (ACT) group according to the treatments they received. The primary outcome was time to achieve sustained remission, assessed by a reduction in modified McCluskey’s scleritis scores. Other outcomes included changes in McCluskey’s scores, scleritis flares, best-corrected visual acuity, and spared glucocorticoid dosage. Patients in the ACT group achieved faster remission than those in the CT group, as the median periods before remission were 4 months vs. 2.5 months (p = 0.016). Scleritis flares occurred in 11/11 eyes in the CT group and 5/12 eyes in the ACT group (p = 0.005). Successful glucocorticoid sparing was realized in both groups, but the ACT group made it faster. No severe adverse events were observed. Data suggest that adalimumab plus conventional therapy could shorten the time to remission, reduce disease flares, and accelerate glucocorticoid withdrawal compared with conventional therapy alone.
    Type of Medium: Online Resource
    ISSN: 2077-0383
    Language: English
    Publisher: MDPI AG
    Publication Date: 2022
    detail.hit.zdb_id: 2662592-1
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 2
    Online Resource
    Online Resource
    MDPI AG ; 2021
    In:  Applied Sciences Vol. 11, No. 3 ( 2021-01-23), p. 1016-
    In: Applied Sciences, MDPI AG, Vol. 11, No. 3 ( 2021-01-23), p. 1016-
    Abstract: In the process of urbanization in developing countries, creating enough jobs to realize the transition from an agricultural population to a non-agricultural population is a major goal of development. The differences and localities of cities need to be considered in the policymaking process. This study estimated the local employment multipliers of expanding cities in China and calculated the employment multiplier of each city. First, there are obvious differences in the size of employment multipliers across cities; therefore, it is necessary to adopt different policies in employment promotion. Second, an inverted-U-shape relationship is detected between employment multiplier and city size, namely the larger the city, the greater the employment multiplier, but when the city size exceeds a certain value, the employment multiplier begins to decline. Third, different degrees of influence are generated by factors for cities at different levels of economic development. Based on the research results, we suggest that expansion of the trade sector be promoted in small- and medium-sized cities, to give full play to its employment multiplier effect; meanwhile, in large cities, the degree of specialization of the trade sector and diversification of the non-trade sector should be improved.
    Type of Medium: Online Resource
    ISSN: 2076-3417
    Language: English
    Publisher: MDPI AG
    Publication Date: 2021
    detail.hit.zdb_id: 2704225-X
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...